

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C12N 15/13, C07K 15/28 C12P 21/08, A61K 39/395	<b>A1</b>	<b>(11) International Publication Number:</b> WO 92/06193 <b>(43) International Publication Date:</b> 16 April 1992 (16.04.92)
<b>(21) International Application Number:</b> PCT/GB91/01726 <b>(22) International Filing Date:</b> 4 October 1991 (04.10.91) <b>(30) Priority data:</b> 9021679.7                      5 October 1990 (05.10.90)                      GB  <b>(71)(72) Applicants and Inventors:</b> GORMAN, Scott, David [US/GB]; 167 Cambridge Road, Great Shelford, Cambridge CB2 5JN (GB). ROUTLEDGE, Edward, Graham [GB/GB]; 53 Eland Way, Cherry Hinton, Cambridge CB1 4XQ (GB). WALDMANN, Herman [GB/GB]; 11 Gurney Way, Cambridge CB4 2ED (GB).  <b>(74) Agent:</b> STEPHENSON, Gerald, Frederick; Patents Department, National Research Development Corporation, 101 Newington Causeway, London SE1 6BU (GB).		<b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ANTIBODIES DIRECTED AGAINST CD3  <b>(57) Abstract</b>  Ligands with a binding affinity for the CD3 antigen having at least one CDR which is of different origin to the variable framework region and/or the constant region of the ligand, the at least one CDR being selected from the amino acid sequences: (a) Ser-Phe-Pro-Met-Ala, (b) Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly, (c) Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr, (d) Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-Tyr-Val-His, (e) Asp-Asp-Asp-Lys-Arg-Pro-Asp, (f) His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val, and conservatively modified variants thereof, are of therapeutic value, particularly in the control of graft rejection.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE <sup>+</sup>	Germany	MC	Monaco	US	United States of America
DK	Denmark				

<sup>+</sup> Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## ANTIBODIES DIRECTED AGAINST CD3

This invention relates to antibodies, in particular to re-shaped antibodies directed against the CD3 antigen on the surface of human T-cells.

Antibodies, or immunoglobulins, comprise two heavy chains  
05 linked together by disulphide bonds and two light chains, each  
light chain being linked to a respective heavy chain by disulphide  
bonds in a "Y" shaped configuration. The two "arms" of the  
antibody are responsible for antigen binding, having regions where  
the polypeptide structure varies, and are termed Fab' fragments  
10 (fragment - antigen - binding) or F(ab')<sub>2</sub> which represents two Fab'  
arms linked together by disulphide bonds. The "tail" or central  
axis of the antibody contains a fixed or constant sequence of  
peptides and is termed the Fc fragment (fragment - crystalline).  
The production of monoclonal antibodies was first disclosed by  
15 Kohler and Milstein (Kohler & Milstein, Nature, 256, 495-497  
(1975)). Such monoclonal antibodies have found widespread use as  
diagnostic agents and also in therapy.

Each heavy chain has at one end a variable domain followed by a  
number of constant domains. Each light chain has a variable domain  
20 at one end and a constant domain at its other end, the light chain  
variable domain being aligned with the variable domain of the heavy  
chain and the light chain constant domain being aligned with the  
first constant domain of the heavy chain (CH1). The constant  
domains in the light and heavy chains are not involved directly in  
25 binding the antibody to antigen. The light chain constant region  
and the CH1 region of the heavy chain account for 50% of each Fab'  
fragment.

The variable domains of each pair of light and heavy chains  
form the antigen binding site. The domains on the light and heavy  
30 chains have the same general structure and each domain comprises  
four framework regions whose sequences are relatively conserved,  
connected by three complementarity determining regions (CDRs)

- 2 -

(Kabat et al., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services (1987)). The four framework regions largely adopt a beta-sheet conformation and the CDRs form loops connecting, and in some cases forming part of, the beta-sheet structure. The CDRs are held in close proximity by the framework regions and, with the CDRs from the other domain, contribute to the formation of the antigen binding site.

In recent years, molecular biology techniques have allowed the production of a wide range of heterologous polypeptides by transformation of host cells with DNA sequences coding for the desired polypeptide. Immunoglobulin polypeptides have been produced by recombinant DNA techniques, see for example EP-A-0 088 994 (Schering Corporation), EP-A-1 102 634 (Takeda Chemical Industries Ltd.) and EP-A-0 125 023 (Genentech Inc.). These techniques have also allowed the stable introduction of immunoglobulin genes into myeloma cells.

When murine or rat monoclonal antibodies or even part human chimeric antibodies (antibodies where the antigen binding portion of an immunoglobulin is attached to at least part of another protein by a peptide linkage) comprising a mouse or rat variable domain is injected into a human in therapy, the human body's immune system could recognise that variable domain as foreign and thus produce an immune response. Hence, upon repeated injections of the mouse or rat monoclonal or chimeric antibody into humans, the effectiveness would be lost or reduced by the reaction of the body's immune system against the foreign antibody.

EP-A-0 239 400 (Winter) describes a monoclonal antibody in which only the CDRs of the antibody will be foreign to the body in order to minimise side effects due to its antigenicity if used for human therapy. Although, for example, human, mouse and rat framework regions have characteristic sequences, there seem to be no characteristic features which distinguish human from mouse and rat CDRs. Thus, an antibody comprised of mouse or rat CDRs in a human framework may well be no more foreign to the body than a genuine human antibody.

- 3 -

It is not clear however that the method of "humanizing" antibodies described in the above application will be suitable for application as a general method to all antibodies. Antibodies have either kappa or lambda light chains and one of alpha, mu, gamma, epsilon or delta heavy chains, specific combinations of which may make the above method of humanising antibodies inapplicable.

Until now, all of the humanised antibodies have contained a light chain of the kappa type. However, it has now been found possible to humanise an antibody directed against the human T-cell CD3 antigen (the monoclonal antibody secreted by the rat hybridoma YTH12.5.14.2 hereinafter referred to as YTH12.5), even though the antibody has a lambda type light chain. The presence of the lambda light chain required a different approach from that used for the humanisation of the mouse monoclonal antibody as described in EP-A-0 239 400.

Accordingly the present invention comprises a ligand with a binding affinity for the CD3 antigen having at least one CDR which is of different origin to the variable framework regions and/or constant regions of the ligand, the at least one CDR being selected from the amino acid sequences:

- (a) Ser-Phe-Pro-Met-Ala,
  - (b) Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly,
  - (c) Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr,
  - (d) Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-Tyr-Val-His,
  - (e) Asp-Asp-Asp-Lys-Arg-Pro-Asp,
  - (f) His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val,
- and conservatively modified variants thereof.

The term "conservatively modified variants" is one well known in the art and indicates variants containing changes which are substantially without effect on antibody-antigen affinity.

- 4 -

The CDRs of the invention are situated within framework regions of the heavy chain (for (a), (b) and (c)) and light chain (for (d), (e) and (f)) variable domains. Moreover, in many but not all cases the ligand will also comprise a constant region. It is possible for the at least one CDR to be of the same origin as its variable framework region but of a different origin from the constant region, for example in a part human chimeric antibody. However, more commonly the at least one CDR will be of different origin from the variable framework regions, for example in a single domain ligand which does not contain a constant region as discussed hereinafter, and usually also of different origin from the constant region where one is present, for example in an antibody or fragment thereof.

Ligands according to the invention may contain varying numbers of CDRs. Thus, for example, the entities known as molecular recognition units contain a single CDR, but of rather greater interest among ligands which do not contain both a heavy and light chain are the single domain ligands described in European Patent Application No. 0 368 684 which contain three CDRs.

In a preferred embodiment of the invention, therefore, the ligand has three CDRs corresponding to the amino acid sequences (a), (b) and (c) above or conservatively modified variants thereof and/or three CDRs corresponding to amino acid sequences (d), (e) and (f) or conservatively modified variants thereof, the heavy chain CDRs (a), (b) and (c) being of most importance.

The present invention is however of particular interest in relation to whole antibodies or fragments thereof containing both heavy and light chain variable regions. Thus the ligand of the invention preferably has the form of an antibody or fragment thereof with a binding affinity for the CD3 antigen having a heavy chain with at least one CDR selected from the amino acid sequences:

- (a) Ser-Phe-Pro-Met-Ala,
- (b) Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly,
- (c) Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr,

- 5 -

and conservatively modified variants thereof, and/or a light chain with at least one CDR selected from the amino acid sequences:

(d) Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-Tyr-Val-His,

(e) Asp-Asp-Asp-Lys-Arg-Pro-Asp,

05 (f) His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val,

and conservatively modified variants thereof.

Although as indicated hereinbefore, ligands according to the invention do not have to contain both one or more of the specified heavy chain CDRs and one or more of the specified light chain CDRs, 10 the antibodies or fragments thereof will usually do so. The CDRs (a), (b) and (c) are arranged in the rat hybridoma YTH12.5 heavy chain in the sequence: framework region 1/(a)/framework region 2/(b)/framework region 3/(c)/framework region 4 in a leader → constant region direction and the CDRs (d), (e) and (f) 15 are arranged in the hybridoma light chain in the sequence: framework region 1/(d)/framework region 2/(e)/framework region 3/(f)/framework region 4 in a leader → constant region direction. It is preferred, therefore, that where all three are present the heavy chain CDRs are arranged in the sequence (a), (b), (c) in a 20 leader → constant region direction and the light chain CDRs are arranged in the sequence (d), (e), (f) in a leader → constant region direction.

It should be appreciated that it may be possible to have heavy chains and particularly light chains containing only one or two of 25 the CDRs (a), (b) and (c) and (d), (e) and (f), respectively. However, although the presence of all six CDRs defined above is therefore not necessarily required in an antibody or fragment thereof according to the present invention, all six CDRs will most usually be present. A particularly preferred antibody or fragment 30 thereof therefore has a heavy chain with three CDRs comprising the amino acid sequences (a), (b) and (c) or conservatively modified variants thereof and a light chain with three CDRs comprising the amino acid sequences (d), (e) and (f) or conservatively modified variants thereof in which the heavy chain CDRs are arranged in the 35 order (a), (b), (c) in the leader constant region direction and the

- 6 -

light chain CDRs are arranged in the order (d), (e), (f) in the leader constant region direction.

The invention may be applied to antibodies having a "Y" shaped configuration which have two identical light and two identical heavy chains and are thus bivalent with each antigen binding site having an affinity for the CD3 antigen. Alternatively, Fab' or F(ab')<sub>2</sub> fragments retaining the CDRs may be prepared. The invention is also applicable to antibodies and, where appropriate, fragments thereof, in which only one of the arms of the antibody has a binding affinity for the CD3 antigen. Such antibodies may take various forms. Thus the other arm of the antibody may have a binding affinity for an antigen other than CD3 so that the antibody is a bispecific antibody, for example as described in U.S. Patent No. 4,474,893 and European Patent Applications Nos. 87907123.1 and 87907124.9. Alternatively, the antibody may have only one arm which exhibits a binding affinity, such an antibody being termed "monovalent".

Monovalent antibodies (or antibody fragments) may be prepared in a number of ways. Glennie and Stevenson (Nature, 295, 712-713, (1982)) describe a method of preparing monovalent antibodies by enzymic digestion. Stevenson et al. describe a second approach to monovalent antibody preparation in which enzymatically produced Fab' and Fc fragments are chemically cross-linked (Anticancer Drug Design, 3, 219-230 (1989)). In these methods the resulting monovalent antibodies have lost one of their Fab' arms. A third method of preparing monovalent antibodies is described in European Patent No. 131424. In this approach the "Y" shape of the antibody is maintained, but only one of the two Fab' domains will bind to the antigen. This is achieved by introducing into the hybridoma a gene coding for an irrelevant light chain which will combine with the heavy chain of the antibody to produce a mixture of products in which the monovalent antibody is the one of interest.

More preferably, however, the monovalent CD3 antibodies of the invention are prepared by a new method. This involves the introduction into a suitable expression system, for example a cell



- 7 -

system as described hereinafter, together with genes coding for the heavy and light chains, of a gene coding for a truncated heavy chain in which the variable region domain and first constant region domain of the heavy chain are absent, the gene lacking the exon for each of these domains. This results in the production by the cell system of a mixture of (a) antibodies which are complete bivalent antibodies, (b) antibody fragments consisting only of two truncated heavy chains (i.e. an Fc fragment) and (c) fragments of antibody which are monovalent for the CD3 antigen, consisting of a truncated heavy chain and a light chain in association with the normal heavy chain. Such an antibody fragment (c) is monovalent since it has any only one Fab' arm. Production of a monovalent antibody in the form of such a fragment by this method is preferred for a number of reasons. Thus, the resulting antibody fragment is easy to purify from a mixture of antibodies produced by the cell system since, for example, it may be separable simply on the basis of its molecular weight. This is not possible in the method of European Patent No. 131424 where the monovalent antibody produced has similar characteristics to a bivalent antibody in its size and outward appearance. Additionally, the production of a monovalent antibody fragment by the new method uses conditions which can more easily be controlled and is thus not as haphazard as an enzyme digestion/chemical coupling procedure which requires the separation of a complex reaction product, with the additional advantage that the cell line used will continue to produce monovalent antibody fragments, without the need for continuous synthesis procedures as required in the enzyme digestion/chemical coupling procedure.

As indicated, the procedure just described for the preparation of monovalent antibody fragments is new and it may be applied to the production of antibody fragments in which the single binding affinity is for other than the CD3 antigen. Accordingly the present invention includes a process for the preparation of a monovalent antibody fragment which comprises culturing an expression system containing genes coding for the antibody heavy and light chains and a gene coding for a truncated heavy chain in

- 8 -

which the variable domain and first constant region domain are absent to thereby effect expression of an antibody fragment possessing only one Fab' domain per Fc domain.

05 The CDRs of the invention are obtained from a rat CD3 antibody. Accordingly, although the variable domain framework regions can take various forms, they are preferably derived from rat or human antibodies. One possibility is for the ligand to have variable domain frameworks corresponding to that in the YTH12.5 hybridoma although the constant region will then necessarily differ  
10 from that of this hybridoma. However the antibody of the invention is preferably in the humanised form as regards both the variable domain frameworks and as discussed hereinafter, the constant region.

Accordingly, the invention further comprises a ligand or an  
15 antibody or a fragment thereof in which the CDR or CDRs are combined with variable domain framework regions of or derived from those of human origin. Certain human variable domain framework sequences will be preferable for the grafting of the CDR sequences according to the invention, since the 3-dimensional conformation of  
20 the CDRs will be better maintained in such sequences and the antibody will retain a high level of binding affinity for the antigen. Desirable characteristics in such variable domain frameworks are the presence of key amino acids which maintain the structure of the CDR loops in order to ensure the affinity and  
25 specificity of the antibody for the CD3 antigen, the lambda type being preferred for the light chain.

We have identified human variable region frameworks which are particularly suitable for use in conjunction with the CDRs of the present invention. The heavy chain variable (V) region frameworks  
30 are those coded for by the human VH type III gene VH26.D.J. which is from the B cell hybridoma cell line 18/2 (Genbank Code: Huminghat, Dersimonian et al., Journal of Immunology, 139, 2496-2501). The light chain variable region frameworks are those of the human V<sub>L</sub> type VI gene SUT (Swissprot code; LV6CSHum,  
35 Solomon et al. In Glenner et al (Eds), Amyloidosis, Plenum Press N.Y., 1986, p.449.

- 9 -

The one or more CDRs of the heavy chain of the rat anti-CD3 antibody are therefore preferably present in a human variable domain framework which has the following amino acid sequence reading in the leader → constant region direction, CDR indicating a CDR (a), (b) or (c) as defined hereinbefore, a conservatively modified variant thereof or an alternative CDR:-

05 Glu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-  
Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Ser-/CDR/-  
Trp-Val-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser-/CDR/-  
10 Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-  
Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Ala-Lys-  
/CDR/-Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser.

In a preferred antibody containing all three CDRs, the heavy chain variable region comprises the following sequence:-

15 Glu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-  
Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Ser-Ser-Phe-  
Pro-Met-Ala-Trp-Val-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-  
Ser-Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-  
Lys-Gly-Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-  
20 Leu-Gln-Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-  
Ala-Lys-Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr-Trp-Gly-Gln-Gly-  
Thr-Leu-Val-Thr-Val-Ser-Ser.

Similarly, the one or more CDRs of the light chain of the rat CD3 antibody are therefore preferably present in a human variable domain framework which has the following amino acid sequence reading in the leader → constant region direction, CDR indicating a CDR (d), (e) and (f) as defined hereinbefore, a conservatively modified variant thereof or an alternative CDR:-

Asp-Phe-Met-Leu-Thr-Gln-Pro-His-Ser-Val-Ser-Glu-Ser-Pro-Gly-Lys-  
30 Thr-Val-Ile-Ile-Ser-Cys-/CDR/-Trp-Tyr-Gln-Gln-Arg-Pro-Gly-Arg-Ala-  
Pro-Thr-Thr-Val-Ile-Phe-/CDR/-Gly-Val-Pro-Asp-Arg-Phe-Ser-Gly-Ser-  
Ile-Asp-Arg-Ser-Ser-Asn-Ser-Ala-Ser-Leu-Thr-Ile-Ser-Gly-Leu-Gln-  
Thr-Glu-Asp-Glu-Ala-Asp-Tyr-Tyr-Cys-/CDR/-Phe-Gly-Gly-Gly-Thr-Lys-  
Leu-Thr-Val-Leu.

- 10 -

In a preferred antibody containing all three CDRs the light chain variable region comprises the following sequence:-

Asp-Phe-Met-Leu-Thr-Gln-Pro-His-Ser-Val-Ser-Glu-Ser-Pro-Gly-Lys-  
Thr-Val-Ile-Ile-Ser-Cys-Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-  
05 Tyr-Val-His-Trp-Tyr-Gln-Gln-Arg-Pro-Gly-Arg-Ala-Pro-Thr-Thr-Val-  
Ile-Phe-Asp-Asp-Asp-Lys-Arg-Pro-Asp-Gly-Val-Pro-Asp-Arg-Phe-Ser-  
Gly-Ser-Ile-Asp-Arg-Ser-Ser-Asn-Ser-Ala-Ser-Leu-Thr-Ile-Ser-Gly-  
Leu-Gln-Thr-Glu-Asp-Glu-Ala-Asp-Tyr-Tyr-Cys-His-Ser-Tyr-Val-Ser-  
Ser-Phe-Asn-Val-Phe-Gly-Gly-Gly-Thr-Lys-Leu-Thr-Val-Leu.

10 The variable domains comprising one or more CDRs as described above, preferably in the humanised form having human antibody-derived framework regions, may conveniently be attached to another protein or carrier, or to constant domains of light and heavy chains of antibodies.

15 The nature of the heavy and light chain constant regions has less effect on binding affinity than that of the variable domain framework and these can be based on antibodies of different types as desired, but are preferably of or are derived from those of human origin and may be of various different classes although for  
20 the light chain the constant region will most usually be of the lambda type and for the heavy chain it may conveniently be of an IgG class, particularly IgG1. Thus the constant domains may conveniently be selected to have desired effector functions appropriate to the intended therapeutic use of the antibody.

25 It will also be appreciated that an antibody according to the invention may be used in a form which retains the CDRs but lacks other parts of the molecule not essential to its binding function. In particular as indicated hereinbefore, Fab' and F(ab')<sub>2</sub> fragments may be used, or the variable regions incorporating the CDRs of the  
30 invention may be attached to a suitable protein or carrier molecule.

It is well recognised in the art that the replacement of one amino acid with another amino acid having similar properties, for example the replacement of a glutamic acid residue with an aspartic acid residue, may not substantially alter the properties or  
35 structure of the peptide or protein in which the substitution or

- 11 -

substitutions were made. Thus, the invention includes those CDR amino acid sequences in which such a substitution or substitutions have occurred without substantially altering the binding affinity and specificity of the CDRs. Alternatively, deletions may be made  
05 in the amino acid residue sequence of the CDRs or the sequences may be extended at one or both of the N- and C-termini whilst still retaining activity.

As indicated, therefore, the invention extends to ligands in which the CDRs may be conservatively modified to provide a variant  
10 thereof which retains a binding affinity for the CD3 antigen. Preferred ligands are such that the affinity constant for the antigen is  $10^5$  mole<sup>-1</sup> or more, for example up to  $10^{12}$  mole<sup>-1</sup>. Ligands of different affinities may be suitable for different uses so that, for example, an affinity of  $10^6$ ,  $10^7$  or  $10^8$  mole<sup>-1</sup> or more  
15 may be appropriate in some cases. However ligands with an affinity in the range of  $10^6$  to  $10^8$  mole<sup>-1</sup> will often be suitable. Conveniently the ligands also do not exhibit any substantial binding affinity for other antigens. Binding affinities of the ligand and ligand specificity may be tested by assay procedures  
20 such as those described in the Examples section hereinafter, (Effector Cell Retargeting Assay), or by techniques such as ELISA and other immunoassays.

The ligands of the invention may be prepared in a number of ways. Most conveniently, however, appropriate gene constructs for  
25 the constant and variable regions of the heavy and light chains which are present in the ligand are separately obtained and then inserted in a suitable expression system. Antibody fragment may be prepared from whole antibody molecules in the usual manner or, as described for monovalent antibody fragments hereinbefore, may be  
30 produced directly by the expression system.

Genes encoding the variable domains of a ligand of the desired structure may be produced and conveniently attached to genes encoding the constant domains of an antibody of the desired isotype and therapeutic applicability. These constant genes may be  
35 obtained from hybridoma cDNA or from the chromosomal DNA or by

- 12 -

mutagenesis (site directed) of such genes to produce constant regions with novel properties. Genes encoding the variable regions may also be derived by gene synthesis techniques used in the identification of the CDRs contained herein. Suitable cloning vehicles for the DNA may be of various types.

Expression of these genes through culture of a cell system to produce a functional CD3 ligand is most conveniently effected by transforming a suitable prokaryotic or particularly eukaryotic cell system, particularly an immortalised mammalian cell line such as a myeloma cell line, for example the YB2/3.01/Ag20 (hereinafter referred to as Y0) rat myeloma cell, or Chinese hamster ovary cells (although the use of plant cells is also of interest), with expression vectors which include DNA coding for the various antibody regions, and then culturing the transformed cell system to produce the desired antibody. Such general techniques of use for the manufacture of ligands according to the present invention are well known in the very considerable art of genetic engineering and are described in publications such as "Molecular Cloning" by Sambrook, Fritsch and Maniatis, Cold Spring Harbour Laboratory Press, 1989 (2nd edition). The techniques are further illustrated by the Examples contained herein.

Accordingly, the invention further comprises DNA sequences encoding the CDRs of the ligand/antibody of the invention. A group of nucleotide sequences coding for the CDRs (a) to (f) described hereinbefore is as indicated under (a) to (f) below, respectively, but it will be appreciated that the degeneracy of the genetic code permits variations to be made in these sequences whilst still encoding for the CDRs' amino acid sequences.

(a) AGCTTTCCAA TGGCC

(b) ACCATTAGTA CTAGTGGTGG TAGAACTTAC TATCGAGACT CCGTGAAGGG C

(c) TTTCGGCAGT ACAGTGGTGG CTTTGATTAC

(d) ACACTCAGCT CTGGTAACAT AGAAAACAAC TATGTGCAC

(e) GATGATGATA AGAGACCGGA T

(f) CATTCTTATG TTAGTAGTTT TAATGTT

- 13 -

The invention also particularly includes larger DNA sequences which comprise (1) DNA expressing human heavy chain framework regions and one or more of (a), (b) and (c), and (2) DNA expressing human light chain framework regions and one or more of (d), (e) and (f). A specific example of such DNA is that sequence (1) indicated below which codes for the CDRs (a), (b) and (c) arranged in the heavy chain framework coded for by the human VH type III gene VH26.D.J. as discussed hereinbefore and that sequence (2) indicated below which codes for the CDRs (d), (e) and (f) arranged in the light chain framework coded for by the human  $V_L\lambda$  type VI gene SUT. The CDR sequences (a), (b), (c), (d), (e) and (f) have been underlined.

- (1) GAGGTCCAAC TGCTGGAGTC TGGGGGCGGT TTAGTGCAGC CTGGAGGGTC  
CCTGAGACIC TCCTGTGCAG CCTCAGGATT CACTTTCAGT AGCTTTCCAA  
15 TGGCCTGGGT CCGCCAGGCT CCAGGGAAGG GTCTGGAGTG GGTCTCAACC  
ATTAGTACTA GTGGTGGTAG AACTTACTAT CGAGACTCCG TGAAGGGCCG  
ATTCATATC TCCAGAGATA ATAGCAAAAA TACCCTATAC CTGCAAATGA  
ATAGTCTGAG GGCTGAGGAC ACGGCCGTCT ATTACTGTGC AAAATTTTCGG  
CAGTACAGTG GTGGCTTTGA TTACTGGGGC CAAGGGACCC TGGTCACCGT  
20 CTCCTCA
- (2) GACTTCATGC TGA
- 25 GACTCAGCC CCACTCTGTG TCTGAGTCTC CCGGAAAGAC  
AGTCATTATT TCTTGACAC TCAGCTCTGG TAACATAGAA AACAACTATG  
TGCACTGGTA CCAGCAAAGG CCGGGAAGAG CTCCCACCAC TGTGATTTTC  
GATGATGATA AGAGACCGGA TGGTGTCCCT GACAGGTTCT CTGGCTCCAT  
TGACAGGTCT TCCAACTCAG CCTCCCTGAC AATCAGTGGT CTGCAA
- 30 AACTG  
AAGATGAAGC TGA
- CTACTAC TGTCATTCTT ATGTTAGTAG TTTTAATGTT  
TTCGGCGGTG GAACAAAGCT CACTGTCCTT

The humanised ligands in accordance with the invention have therapeutic value. In particular, a reshaped antibody, especially a humanised antibody, with a specificity for the antigen CD3 has valuable applications in immunosuppression, particularly in the control of graft rejection, and potentially also in other areas such as the treatment of cancer, especially of lymphoid malignancies and indeed lymphomas in general.

- 14 -

In a further aspect, the invention thus includes a method of treating patients with lymphomas or for immunosuppression purposes, for instance in a case where graft rejection may occur, comprising administering a therapeutically effective amount of a ligand in accordance with the invention.

Ligands in accordance with the invention may be formulated for administration to patients by administering the said ligand together with a physiologically acceptable diluent or carrier. The ligands are preferably administered in an injectable form together with such a diluent or carrier which is sterile and pyrogen free. By way of guidance it may be stated that a suitable dose of ligand is about 1-10 mg injected daily over a time period of, for example 10 days. In order to avoid a severe first dose response, suitable anti-cytokines may be administered with the first injection. Such a procedure facilitates the use of a dosage towards the upper end of the 1-10 mg range or even somewhat higher.

The invention is illustrated by the following Examples which are illustrated by the drawings listed below:

DESCRIPTION OF THE DRAWINGS

Figure 1 :

Position and sequence of the oligonucleotide forward and backward primers used in the cDNA synthesis and PCR amplification of the rat YTH12.5 VL lambda gene.

Figure 2 :

Cloning and reshaping of the YTH12.5 VH gene.

Figure 3 :

Reshaping of the YTH12.5 VL gene and construction of the YTH12.5 immunoglobulin light chain expression vector.

Figure 4 :

Construction of the reshaped YTH12.5 immunoglobulin heavy chain expression vector.

Figure 5 :

Construction of the truncated human IgG1 heavy chain (tH) gene expression vector.



- 15 -

Figure 6 :

Native PAGE of protein-A purified total immunoglobulin secreted by cells co-transfected with the humanised CD3 heavy, light and truncated heavy chain gene expression vectors.

05 Figure 7 :

Reduced (7a) and non-reduced (7b) SDS-PAGE of the antibody molecules corresponding to native PAGE bands 1, 2 and 3 (lanes 1, 2 and 3 respectively).

Figure 8 :

10 Humanised bivalent and monovalent CD3 antibodies were tested for their ability to direct T-cell killing of Fc receptor-bearing U937 cells. Rat bivalent YTH12.5 CD3 monoclonal antibody and the humanised CDw52 antibody were tested as controls.

Figure 9 :

15 Comparison of antibody binding of humanised monovalent and bivalent CD3 antibodies with rat bivalent YTH12.5 CD3 monoclonal antibody. The humanised CDw52 antibody was included as a negative control.

Figure 10 :

20 Humanised bivalent and monovalent CD3 monoclonal antibodies were tested for their ability to direct complement mediated lysis of human T-cell blasts. Rat bivalent YTH12.5 CD3 monoclonal antibody was tested for comparison.

EXAMPLES

25 The invention is illustrated by the following Examples, which employ techniques such as those described in Molecular Cloning by Sambrook et al.

EXAMPLE 1 : CULTURE OF RAT HYBRIDOMA AND CHINESE HAMSTER OVARY CELLS

YTH12.5 rat hybridoma cells secreting rat gamma-2b antibody specific for the Epsilon chain of the human CD3 antigen complex (Clark et al., Eur. J. Immunol., 19, 381-388 (1989)) were grown or  
30 maintained in Iscove's modification of Dulbecco's medium with antibiotics and 5% bovine foetal calf serum respectively. YO cells, a non-antibody secreting rat myeloma cell line were similarly cultured (Clark and Milstein, Somatic Cell Genetics, 7  
35 (6) 657-666, (1981) and European Patent 0043718).

- 16 -

Chinese hamster ovary (CHO) cells with a dihydrofolate reductase negative (dhfr<sup>-</sup>) phenotype were cultured in medium supplemented with hypoxanthine and thymidine.

EXAMPLE 2 : CLONING THE YTH12.5 HYBRIDOMA IMMUNOGLOBULIN VARIABLE

05 HEAVY (VH) AND VARIABLE LIGHT (VL) REGION GENES

YTH12.5 cells were lysed with a solution of guanidine thiocyanate and total RNA was isolated by centrifugation through a CsCl cushion (Chirgwin *et al.*, Biochemistry, 18, 5294 (1987)). Messenger RNA was prepared from this by affinity chromatography on  
10 oligo-dT cellulose (Maniatis *et al.*, Molecular Cloning. A laboratory manual. Published by Cold Spring Harbour Laboratory. (1982)).

CDNA synthesis of the YTH12.5 VH and VL region genes and their subsequent amplification using the Polymerase Chain Reaction (PCR) was carried out as described by Orlandi *et al.*, Proc. Natl. Acad.  
15 Sci., USA, 86, 3833-3837 (1989)). The oligonucleotide primers VH1-forward and VH1-backward, and the specialised M13VHPCR1 cloning vector used during this process for the VH gene were also described by Orlandi *et al.*. CDNA synthesis and amplification of the VL gene was performed using forward and backward oligonucleotide primers  
20 derived from a published rat lambda VL gene sequence (Steen *et al.*, Gene, 55, 75-84 (1987)) (Figure 1). Figure 1 shows the position and sequence of the oligonucleotide forward and backward primers used in the cDNA synthesis and PCR amplification of the YTH12.5 rat VL lambda gene. In Figure 1, FW denotes a framework region, VL  
25 denotes the light chain variable region, JL the light chain joining region and CL denotes the 5' end of the light chain constant region.

The VL PCR product was cloned by blunt end ligation into HincII cut M13mp18 (Figure 2). The resulting clone was known as M13 1a. Dideoxy-DNA sequencing was used to identify clones containing VH  
30 and VL inserts.

EXAMPLE 3 : SELECTION OF THE VARIABLE DOMAIN FRAMEWORK REGIONS

A search of the Genbank, EMBL and Swissprot databases identified those known human VH and VL amino acid sequences which had the highest degree of homology to the YTH12.5 VH and VL region  
35 genes. When choosing the final human sequence to reshape to,

- 17 -

preference was given to the one where the length of the frameworks and complementarity determining regions (CDRs; as defined by Kabat *et al.*, Sequences of proteins of immunological interest; 4th edition. Publ. US Department of Health and Human Services (1987)) were closest to those of the corresponding rat gene. The frameworks chosen for the reshaping of the rat VH and VL genes were from the human VH type III gene VH26-D-J (from the B cell hybridoma cell line 18/2; Genbank code: Humighat. Derismonian *et al.*, J. Immunol., 139, 2496-2501 (1987)) and the human VL lambda type VI gene SUT (Swissprot code: Lv6c\$h. Solomon *et al.*, (In) Amyloidosis, pp 449-462. Eds. Glenner, G. G., Osserman, E.F., Benditt, E.P., Calkins, E., Cohen, A. S. and Zucker-Franklin, D. Publ. Plenum Press, New York (1986)), respectively.

EXAMPLE 4 : RESHAPING THE YTH12.5 VH GENE

The procedure for reshaping the YTH12.5 VH gene is indicated in Figure 2. In Figure 2, V, D and J denote the variable, diversity and joining region of the VH gene respectively. The leader sequence is denoted as L, and the immunoglobulin gene promoter as Ig Pro.

Oligonucleotide site directed mutagenesis was performed using the mutagenesis kit supplied by Amersham International PLC. Six mutagenic oligonucleotides ranging in length from 30 to 60 bases were used which were complementary to the positive DNA strand of the VH gene. The M13 clone 1a was used as the template in the mutagenesis reactions to reshape the frameworks (Figure 2) and mutants were analysed by dideoxy-DNA sequencing. In addition to the mutations necessary for altering the appropriate VH framework codons, a HindIII site was introduced immediately 5' to the VH start codon using a seventh oligonucleotide (Figure 2c); this was to facilitate removal of the M13VHPCR1 immunoglobulin promoter by HindIII digestion. The M13 clone was known as M13 407. The amino acid sequences coded for by the rat VH gene (bottom sequence) and the reshaped VH gene (top sequence) are shown below with the CDRs being underlined in the latter (a dash in the rat sequence indicates identity for that residue with the reshaped sequence):

- 18 -

Glu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-  
Gln - - - Gln - - - - - - - - Arg

Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Ser-Ser-Phe-  
 - Met-Lys - - - - -

05 Pro-Met-Ala-Trp-Val-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-  
 - - - - - Lys - - - - -

Ser-Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-  
 Ala - - - - -

10 Lys-Gly-Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-  
 - - - - - Gly - Ser-Ile - -

Leu-Gln-Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-  
 - - - - - Ser - - - - - Thr - - -

Ala-Lys-Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr-Trp-Gly-Gln-Gly-  
 Ser-Arg - - - - - - - - - -

15 Thr-Leu-Val-Thr-Val-Ser-Ser  
- Thr - - - - -

The sequences shown in the box are coded for by the VH forward and backward PCR primers and may not be the true YTH12.5 VH region sequence.

20 The nucleotide sequence of the reshaped VH gene is shown below with the CDR sequences underlined:

25 GAGGTCCAAC TGCTGGAGTC TGGGGGCGGT TTAGTGCAGC CTGGAGGGTC  
 CCTGAGACTC TCCTGTGCAG CCTCAGGATT CACTTTCAGT AGCTTTCCAA  
TGGCCTGGGT CCGCCAGGCT CCAGGGAAGG GTCTGGAGTG GGTCTCAACC  
ATTAGTACTA GTGGTGGTAG AACTTACTAT CGAGACTCCG TGAAGGGCCG  
 ATCACTATC TCCAGAGATA ATAGCAAAAA TACCCTATAC CTGCAATGA  
 ATAGTCTGAG GGCTGAGGAC ACGGCCGTCT ATTACTGTGC AAAATTTCGG  
CAGTACAGTG GTGGCTTTGA TTACTGGGGC CAAGGGACCC TGGTCACCGT  
 CTCCTCA

- 19 -

EXAMPLE 5 : RESHAPING THE YTH12.5 VL GENE

The procedure for reshaping the YTH12.5 VL gene is indicated in Figure 3. Figure 3(a) shows the strategy for cloning the rat YTH12.5 VL gene. The abbreviations V and J denote the variable and joining regions of the VL gene. C' denotes the 5' end of the rat YTH12.5 lambda constant region. The PCR product was cloned into M13 to give clone M13 13a. Mutagenesis was carried out to introduce and delete restriction enzyme sites. The VL gene was isolated from M13 13a by PvuII-TaqI digestion.

Originally cloned into M13mp18 (Example 2), the YTH12.5 VL gene lacked upstream and downstream signals necessary for gene expression. Therefore, before reshaping, the VL gene was subcloned into the vector M13VKPCR1 (Orlandi et al., Proc. Natl. Acad. Sci., USA, 86, 3833-3837) (1989)) (Figure 3 (c) + (d) along with the Kern-Oz- human lambda constant region gene (CL) (Rabbitts and Forster, Mol. Biol. Med., 1, 11-19 (1983), isolated as shown in Figure 3 (b) from 8KB genomic fragment. In Figure 3 (b), C denotes the human Kern-Oz constant region. The cloning vector M13VKPCR1 was prepared by excising out the humanised kappa light chain variable region (HuVKlys) which constitutes part of the M13VKPCR1 cloning vector. Before the three way ligation of vector, VL and CL could be carried out, site directed mutagenesis was necessary to introduce and/or delete appropriate restriction enzyme sites. Details of this process are illustrated in Figures 3 (a), (b) and (c). The resulting chimaeric rat VL-human CL gene was isolated by NcoI-BamHI digestion and subcloned in between the HindIII and BamHI sites of the vector PHBAPr-1-gpt (Gunning et al., Proc. Natl. Acad. Sci., USA, 84, 4831-4835 (1987)), causing the loss of the M13VKPCR3 immunoglobulin promotor, the NcoI and the HindIII sites.

The gene was finally subcloned as a SalI-BamHI fragment into M13mp18 to produce clone 281, the template for the subsequent reshaping mutagenesis reactions. Mutagenesis was performed as described for the rat VH gene; mutagenic oligonucleotides were made complementary to the negative DNA strand of the VL gene due to the orientation of the gene in the M13mp18 vector. Five

- 20 -

oligonucleotides ranging in length from 27 to 72 nucleotides were used. The amino acid sequences coded for by the rat VL gene (bottom sequence) and the reshaped VL gene (top sequence) are shown below with the CDRs being underlined in the latter (a dash in the rat sequence indicates identity for that residue with the reshaped sequence):

```

05 Asp-Phe-Met-Leu-Thr-Gln-Pro-His-Ser-Val-Ser-Glu-Ser-Pro-Gly-Lys-
    Gln-Ala-Val-Val - - Ala-Asn - - - Thr - Leu - Ser

10 Thr-Val-Ile-Ile-Ser-Cys-Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-
    - - Lys-Leu - - - - - - - - - - - - - - - - - - - - - - -

    Tyr-Val-His-Trp-Tyr-Gln-Gln-Arg-Pro-Gly-Arg-Ala-Pro-Thr-Thr-Val-
    - - - - - - - Leu-Tyr-Glu - - Ser - - - - Met

    Ile-Phe-Asp-Asp-Asp-Lys-Arg-Pro-Asp-Gly-Val-Pro-Asp-Arg-Phe-Ser-
    - Tyr - - - - - - - - - - - - - - - - - - - - - - -

15 Gly-Ser-Ile-Asp-Arg-Ser-Ser-Asn-Ser-Ala-Ser-Leu-Thr-Ile-Ser-Gly-
    - - - - - - - - - - - - - Phe - - - - His-Asn

    Leu-Gln-Thr-Glu-Asp-Glu-Ala-Asp-Tyr-Tyr-Cys-His-Ser-Tyr-Val-Ser-
    Val-Ala-Ile - - - - Ile - Phe - - - - - - - - - - -

    Ser-Phe-Asn-Val-Phe-Gly-Gly-Gly-Thr-Lys-Leu-Thr-Val-Leu
20 - - - - - - - - - - - - - - - - - - - - - - -
  
```

The amino acid sequence shown in the box is coded for by the V $\lambda$  back primer and therefore may or may not be present in the original YTH12.5 V $\lambda$  sequence.

- 21 -

The nucleotide sequence of the reshaped VL gene is shown below with the CDR sequences underlined:

05 GACTTCATGC TGACTCAGCC CCACTCTGTG TCTGAGTCTC CCGGAAAGAC  
 AGTCATTATT TCTTGCACAC TCAGCTCTGG TAACATAGAA AACAACTATG  
TGCACTGGTA CCAGCAAAGG CCGGGAAGAG CTCCCACCAC TGTGATTTTC  
GATGATGATA AGAGACCGGA TGGTGTCCCT GACAGGTTCT CTGGCTCCAT  
 TGACAGGTCT TCCAACCTCAG CCTCCCTGAC AATCAGTGGT CTGCAAACCTG  
 AAGATGAAGC TGACTACTAC TGTCACTCTT ATGTTAGTAG TTTTAATGTT  
 TTCGGCGGTG GAACAAAGCT CACTGTCCTT

10 EXAMPLE 6 : EXPRESSION OF THE RESHAPED YTH12.5 IMMUNOGLOBULIN GENES  
IN DHFR<sup>-</sup>CHO CELLS

An expression vector for the reshaped heavy (H) chain immunoglobulin gene was derived from the vector pHBAPr-1-gpt (gpt-EcoRI xanthine-guanine phosphoribosyl transferase gene) as illustrated schematically in Figures 4 (a), (b) and (c). The human IgG1 genomic constant region gene (HuIgG1) on a 2.2 KB BamHI-BglII fragment of DNA (Takahashi *et al.*, Cell, 29, 671-679 (1982)) was isolated as shown in Figure 4 (b). The human IgG1 genomic constant region was first inserted into the BamHI site of pHBAPr-1-gpt.

20 A 1.65KB fragment of DNA encoding the mouse dhfr gene (Chang *et al.*, Nature, 275, 617-624 (1978)) flanked by SV40 early promoter and SV40 early termination and polyadenylation signals (Subramani *et al.*, Mol. Cell. Biol., 1, 854-864 (1981); with a crippled promoter (isolated as shown in Figure 4 (a)) was then cloned into the EcoRI

25 site, followed by the reshaped YTH12.5 VH gene (see Example 4) in between the vector's HindIII and BamHI sites (to give clone 278).

The reshaped light (L) chain immunoglobulin gene on a SalI-BamHI fragment of DNA was inserted in between the SalI and BamHI sites of the expression vector pHBAPr-1 (Gunning *et al.*, Proc. Natl. Acad. Sci., USA, 84, 4831-4835 (1987)) (to give clone 274). This vector has no eukaryotic cell selectable marker.

30

The H and L chain expression vectors were linearised by digestion with PvuI and then cotransfected into dhfr<sup>-</sup> CHO cells using the transfection reagent DOTMA (Boehringer). Stable

35 transfectants were selected by their ability to grow in

- 22 -

xanthine/hypoxanthine free IMDM containing dialysed foetal bovine calf serum, a property conferred by the H chain expression vector's dhfr gene. Transfectants, cloned in soft agar and cultured in 24-well plates, were screened for antibody production by ELISA.

05 EXAMPLE 7 : ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)

Test cell culture supernatants were titrated in Falcon Microtest III flat-bottomed plates which had previously been coated overnight with 1/4000 polyclonal goat anti-human IgGc antibody (Sigma) in PBS, pH 7.4 at 4°C. The presence of captured human antibody was detected using 1/4000 biotinylated polyclonal goat anti-human lambda L chain antibody (Amersham) followed by 1/1000 biotinylated, streptavidin complexed horse-radish peroxidase (Amersham) and the substrate OPD. PBS containing 0.02% v/v Tween 20 and 1% w/v BSA was used as the antibody diluent after the capture antibody stage. Incubations for the test antibody, detector antibody, peroxidase and substrate were 1 hr, 1 hr, 1 hr and 30 min respectively at 37°C; plates were rinsed 4 times for 3 min in between each stage.

15 EXAMPLE 8 : PREPARATION OF MONOVALENT ANTIBODY (1Fab', 1Fc) BY  
20 THE INTRODUCTION OF AN N-TERMINAL TRUNCATED HUMAN IgG1  
HEAVY CHAIN (tH) GENE INTO AN ANTIBODY SECRETING  
CELL LINE

The human IgG1 genomic constant region gene (Takahashi *et al*, Cell, 29, 671-679 (1982)) on a 2.2 KB BamHI-SphI fragment of DNA in M13Tg131 was digested with PstI and SphI to yield a 1.4 kB length of DNA encoding the hinge and second and third constant region domain (CH2 and CH3) exons. This fragment was blunt end repaired with T4 DNA polymerase to remove the 3' overhanging single stranded DNA ends produced by the PstI and SphI endonucleases. The truncated gene was then inserted into the vector M13VKPCR1 (Orlandi *et al*, Proc. Natl. Acad. Sci., USA, 86, 3833-3837 (1989)) between the vector's PvuII and BamHI sites to provide the gene with a start codon and leader peptide sequence necessary for gene expression. The vector's BamHI site was reconstituted by end repair using the Klenow fragment of DNA polymerase 1 during this



- 23 -

procedure. The completed gene was excised from M13VKPCR1 by digestion with NcoI and BamHI (thus separating the vector's immunoglobulin promotor from the gene) and then inserted between the HindIII and BamHI sites of the expression vector pHBAPro-I-Neo (Gunning et al., Proc. Natl. Acad. Sci., USA, 85, 7719-7723 (1987)) in which expression is controlled by the human  $\beta$  actin promotor to produce the tH expression vector clone 68. The steps described above are summarised in Figure 5.

The completed tH gene is predicted to encode a polypeptide comprising a mouse immunoglobulin heavy chain variable region leader peptide followed by the first three N-terminal amino acids of the humanised anti-lysozyme kappa light chain variable region fused to the hinge-CH2-CH3 domains of human IgG1.

The tH gene expression vector (clone 68) was linearized with PvuI and then transfected into YO or CHO cells along with expression vectors carrying the humanised heavy (vector 276 for YO cells, vector 278 for CHO cells) and light (vector 274) chain genes (see example 6 for details of vectors 274 and 278; vector 276 is identical to 278 with the exception that the EcoRI fragment of DNA carrying the DHFR gene is missing). Transfected YO cells were selected in IMDM containing 5% normal bovine FCS, 2 mg/ml G418, 2  $\mu$ g/ml mycophenolic acid, 250  $\mu$ g/ml xanthine, 13.6  $\mu$ g/ml hypoxanthine and 3.87  $\mu$ g/ml thymidine. Transfected CHO cells were selected in IMDM containing 5% dialysed bovine FCS and 2 mg/ml G418. Transfectants were screened for the secretion of all three immunoglobulin chains by analysis of total immunoglobulin (prepared by protein-A affinity adsorption) on 10-15% gradient native and SDS polyacrylamide gels using a Pharmacia Phast Gel system.

#### Results

Native (non-denaturing) PAGE analysis of total immunoglobulin (for example, from the cell line EGRY068/H+L.3.7) revealed the presence of three major protein bands (Figure 6). Purification of the high molecular weight band (band 1) followed by further PAGE analysis in reducing denaturing conditions showed that it consisted of heavy (H) and light (L) immunoglobulin chains (Figure 7a).

- 24 -

Similarly the protein band of intermediate size (band 2) consisted of H + L + tH polypeptides, and the lower band (band 3) contained only tH polypeptides. The bands can therefore be identified as bivalent antibody, monovalent antibody and Fc molecules respectively. Image analysis of the SDS-PAGE gel using the Pharmacia Phast-Image system indicated that the H, L and tH polypeptides in native PAGE bands 1 and 2 were present within each band in approximately equimolar amounts as expected. Denaturing, non-reducing SDS-PAGE demonstrated that the polypeptides comprising all three native gel protein bands were linked by disulphide bonds. The possibility that the bands represented non-specific aggregates of the H, L and tH polypeptides was therefore ruled out (Figure 7b).

#### EXAMPLE 9 : PURIFICATION OF ANTIBODIES

The monovalent and bivalent humanised CD3 antibodies were purified as follows: Total immunoglobulin was isolated by protein-A affinity chromatography as described by Harlow and Lane (Antibodies: A Laboratory Manual, Publ. Cold Spring Harbor 1988), from the culture supernatant of CHO cells co-transfected with expression vectors carrying the tH, humanised H and L chain genes. The mono- and bivalent antibody species were separated from this mixture by ion-exchange chromatography using an LKB HPLC system fitted with a TSK-5PW-DEAE 7.5 x 60 mm Glaspac column, equilibrated with 20 mM Tris pH 8.5 and eluted with a gradient of the same buffer containing 1M NaCl. The rat YTH12.5 Mab was similarly purified with the exception that ion exchange chromatography was performed in 20 mM piperazine pH 9.5 containing 0.1% betaine. The humanised CDw52 Mab (IgG1) (Reichmann *et al.*, Nature, 332, 323-327, 1988) produced in CHO cells was provided, protein-A purified, by Dr. G. Hale (Cambridge University Division of Immunology). Antibody concentrations were determined using the Lowry assay, and the purity of antibody preparations was assessed by SDS-PAGE on 10-15% gradient gels using a Pharmacia Phast Gel System.

- 25 -

EXAMPLE 10 :COMPETITIVE BINDING ASSAY

05 Aliquots of  $5 \times 10^4$  HPBALL (human peripheral blood acute lymphoblastic leukaemia) cells in 96 well microtitre plates were stained with  $2.0 \mu\text{g ml}^{-1}$  biotinylated monovalent humanised CD3 monoclonal antibody (prepared from the cell line EGRCHOH+L/68.2) in the presence of increasing concentrations of non-biotinylated competitor Mab. After 1 hour the cells were rinsed and stained for a further 1 hour with streptavidin-FITC (Amersham RPN 1232). The  
10 cells were rinsed again and fixed with 1% v/v formaldehyde in PBS. Incubations were performed at  $4^\circ\text{C}$  and PBS containing 0.1% (w/v) sodium azide, 1% w/v BSA and 5% v/v heat inactivated normal rabbit serum was used as the diluent and rinsing solution. The mean cellular fluorescence of approximately 3500 cells per well was  
15 determined using a FACScan (Becton Dickinson).

Comparison of antibody binding

The results are shown in Figure 8 wherein (a) is the CDw52 Mab control, (b) is the humanised monovalent CD3 Mab, (c) is the rat YTH12.5 CD3 Mab and (d) is the humanised bivalent CD3 Mab.  
20  $1-2 \mu\text{g ml}^{-1}$  of humanised bivalent CD3 Mab was sufficient to saturate the CD3 antigen binding sites on  $5 \times 10^4$  HPBALL cells, whereas  $250 \mu\text{g ml}^{-1}$  of the humanised monovalent CD3 Mab was not enough (data not shown). For this reason the monovalent Mab was used as the biotinylated detector in the competitive binding  
25 assays, as relatively low concentrations of the bivalent YTH12.5 rat and humanised CD3 antibodies would be required to achieve a significant degree of competition.

The concentration of the rat and humanised bivalent Mabs required to give 50% competition of the monovalent detector were  
30 very similar. Only 1.3-fold more humanised compared to rat Mab was needed.

- 26 -

A 6-fold to 8.25 fold higher concentration (in separate experiments) of the humanised monovalent Mab was necessary to obtain the same degree of competition as the humanised bivalent Mab. As antibody concentration has been expressed in terms of molar Fab' domain concentration (to account for the presence of 2 and 1 antigen binding sites per bivalent and monovalent molecule respectively), this difference must be indicative of the increase in antibody avidity resulting from the linking of two Fab domains in a bivalent Mab molecule. CD3-antigenic modulation by the bivalent Mab can be discounted as the cause because staining was performed in the presence of 15 mM sodium azide at 4°C. Azide at a concentration of 10 mM has been shown to inhibit antibody-induced redistribution of cell surface molecules (Taylor and Duffus, 1971). Nature, New Biol. 233, p. 225.

EXAMPLE 11 : EFFECTOR CELL RETARGETING ASSAY FOR THE DETECTION OF ANTIBODY WITH HUMAN CD3 ANTIGEN SPECIFICITY

This was performed as described elsewhere (Gilliland et al, Proc. Natl. Acad. Sci., USA, 85, 7719-7723 (1988)). Briefly, <sup>51</sup>Cr labelled U937 human monocytic tumour cells, which express the Fcγ receptor 1 molecule, were used as targets. CD3 antigen positive Fcγ receptor 1 effector cells were generated from human peripheral blood lymphocytes (PBLs) activated with mitogenic CD3 antibody and maintained in medium containing IL-2. Target and effector cells were mixed at a ratio of 1:2 in the presence of test or control antibody. Lysis of the target cells (indicating cross-linking of targets and cytotoxic effectors by CD3 antigen-CD3 antibody and CD3 antibody (Fc)-Fcγ receptor 1 interactions, and hence the presence of CD3 antigen specific antibody) was measured by the quantity of <sup>51</sup>Cr released by the targets into the culture medium. Each antibody dilution was tested in quadruplicate. Humanised CD3 monovalent and bivalent antibodies produced by CHO cell lines were compared with rat YTH12.5 CD3 antibody, humanised anti-CD1 antibody (CDw52) was included as a negative control. The results are shown in Figure 9 wherein (d) is humanised bivalent CD3 Mab, (c) is rat bivalent YTH12.5 CD3 Mab, (b) is humanised

- 27 -

monovalent CD3 Mab and (a) is the CDw52 control. As expected,  $^{51}\text{Cr}$  release from the humanised CDw52 was very low and not affected by increasing or decreasing the amounts of antibody (no dose-response). The humanised CD3 antibodies performed marginally better than the rat YTH12.5 antibody.

EXAMPLE 12 : COMPLEMENT MEDIATED CELL LYSIS (CML)

The CML activity of the humanised CD3 monoclonal antibodies was compared using T-cell blasts as targets (see Example 11 for details of their preparation) and serum from the T-cell donor as the source of complement. The assay was essentially carried out as described by Bindon *et al.*, European Journal of Immunology, 18, 1507-1514 (1988). Briefly, aliquots of  $1 \times 10^5$   $^{51}\text{Cr}$  labelled T-cell blasts in 96 well microtitre plates were incubated for 1 hour at  $37^\circ\text{C}$  in the presence of test antibody (at various concentrations) and a final concentration of human serum of 25% v/v. After the incubation, the cells were pelleted by centrifugation. Half of the supernatant was carefully removed from each well and analysed to determine its  $^{51}\text{Cr}$  content.

The results are shown in Figure 10 wherein (d) is humanised bivalent CD3 Mab, (b) is humanised monovalent CD3 Mab and (c) is rat bivalent Mab. Each point represents the mean of two determinations.

The bivalent humanised CD3 Mab gave no detectable lysis at all even at a concentration of  $100 \mu\text{g ml}^{-1}$ , which exceeds the saturation concentration by a factor of approximately 50. Conversely, the difference between the non-lytic bivalent humanised CD3 Mab and its lytic rat Mab counterpart must be due to the different antibody constant regions as the antigen specificities they possess are the same. It is not a result of expressing the humanised antibody in CHO cells, as antibody produced by YO rat myeloma cells behaved in a similar fashion (data not shown).

- 28 -

The effect on CML activity of making the humanised CD3 Mab monovalent was quite dramatic. Whereas the bivalent Mab gave no lysis at  $100 \mu\text{g ml}^{-1}$ , the monovalent Mab gave almost 30% lysis. This is approximately 2-fold higher than the maximum lysis obtained with the bivalent rat YTH12.5 Mab, but it required an antibody concentration 10-fold higher than that of the rat Mab to achieve it. The need for a higher antibody concentration for monovalent Mab CML may be partly due to the difference in binding avidity previously demonstrated for monovalent and bivalent Mabs; thus a higher concentration of monovalent Mab is needed to bind the same amount of antibody to the cell surface.

Using a Mab which effectively lysis cells with complement is presumably an advantage in situations where cell clearance is the aim, but it may not be of over-riding importance. The performance of the humanised CD3 Mabs in the effector-cell retargetting assay which is dependent on Fc-Fc receptor interactions is therefore encouraging.

#### NOTE

In this specification the amino-acid residues are designated in the standard manner (Pure and Applied Chemistry, 1974, 40, 317 and European Journal of Biochemistry, 1984, 138, 9) as are the nucleotide residues (Molecular Cloning, Sambrook et al., ibid).

- 29 -

CLAIMS

1. A ligand with a binding affinity for the CD3 antigen having at least one CDR which is of different origin to the variable framework region and/or the constant region of the ligand, the at  
05 least one CDR being selected from the amino acid sequences:
- (a) Ser-Phe-Pro-Met-Ala,
  - (b) Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly,
  - (c) Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr,
  - 10 (d) Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-Tyr-Val-His,
  - (e) Asp-Asp-Asp-Lys-Arg-Pro-Asp,
  - (f) His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val,
- and conservatively modified variants thereof.
2. A ligand according to Claim 1 having the three CDRs  
15 corresponding to the amino acid sequences (a), (b) and (c) and/or the three CDRs corresponding to the amino acid sequences (d), (e) and (f).
3. An antibody or fragment thereof with a binding affinity for the CD3 antigen having a heavy chain with at least one CDR which is of  
20 different origin to the variable framework region and/or the constant region thereof, the at least one CDR being selected from the amino acid sequences:
- (a) Ser-Phe-Pro-Met-Ala,
  - (b) Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly,
  - 25 (c) Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr,
- and conservatively modified variants thereof, and/or a light chain with at least one CDR which is of different origin to the variable framework region and/or the constant region thereof, the at least  
30 one CDR being selected from the amino acid sequences:
- (d) Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-Tyr-Val-His,
  - (e) Asp-Asp-Asp-Lys-Arg-Pro-Asp,
  - (f) His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val,
- and conservatively modified variants thereof.

- 30 -

4. A ligand or an antibody or fragment thereof according to any of Claims 1 to 3, in which the three CDRs (a), (b) and (c) or conservatively modified variants thereof are present.
5. An antibody or fragment thereof with binding affinity for the CD3 antigen having a heavy chain with three CDRs which are of different origin to the variable framework region and/or the constant region thereof, the CDRs comprising the amino acid residues
- (a) Ser-Phe-Pro-Met-Ala,
- (b) Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly,
- (c) Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr,
- or conservatively modified variants thereof and a light chain with three CDRs which are of different origin to the variable framework region and/or the constant region thereof, the CDRs comprising the amino acid residues
- (d) Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-Tyr-Val-His,
- (e) Asp-Asp-Asp-Lys-Arg-Pro-Asp,
- (f) His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val,
- or conservatively modified variants thereof, the heavy chain CDRs being arranged in the order (a), (b), (c) in the leader → constant region direction and the light chain CDRs being arranged in the order (d), (e), (f) in the leader → constant region direction.
6. A ligand or an antibody or fragment thereof according to any of Claims 1 to 5, in which the CDR or CDRs are combined with variable domain framework regions which are of or are derived from those of human origin.
7. A ligand or an antibody or fragment thereof according to Claim 6, in which the heavy chain variable domain framework region reading from in the leader → constant region direction comprises
- Glu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Ser-/CDR/-Trp-Val-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser-/CDR/-Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Ala-Lys-/CDR/-Trp-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser, CDR indicating



- 31 -

the presence of a CDR of which at least one is (a), (b) or (c) or a conservatively modified variant thereof.

8. A ligand or an antibody or fragment thereof according to Claim 6 or 7, in which the light chain variable domain framework region  
 05 reading in the leader → constant region direction comprises  
 Asp-Phe-Met-Leu-Thr-Gln-Pro-His-Ser-Val-Ser-Glu-Ser-Pro-Gly-Lys-  
 Thr-Val-Ile-Ile-Ser-Cys-/CDR/-Trp-Tyr-Gln-Gln-Arg-Pro-Gly-Arg-Ala-  
 Pro-Thr-Thr-Val-Ile-Phe-/CDR/-Gly-Val-Pro-Asp-Arg-Phe-Ser-Gly-Ser-  
 Ile-Asp-Arg-Ser-Ser-Asn-Ser-Ala-Ser-Leu-Thr-Ile-Ser-Gly-Leu-Gln-  
 10 Thr-Glu-Asp-Glu-Ala-Asp-Tyr-Tyr-Cys-/CDR/-Phe-Gly-Gly-Gly-Thr-Lys-  
 Leu-Thr-Val-Leu-Gly-Gln-Pro-Lys-Ala-Ala-Pro-Ser-Val-Thr-Leu-Phe-  
 Pro-Pro-Ser-Ser-Glu-Glu-Leu-Gln, CDR indicating the presence of a  
 CDR of which at least one is (d), (e) or (f) or a conservatively  
 modified variant thereof.

15 9. A ligand or an antibody or fragment thereof according to Claim 6  
 having a heavy chain variable domain which comprises  
 Glu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-  
 Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Ser-Ser-Phe-  
 Pro-Met-Ala-Trp-Val-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-  
 20 Ser-Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-  
 Lys-Gly-Arg-Phe-Thr-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-  
 Leu-Gln-Met-Asn-Ser-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-  
 Ala-Lys-Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr-Trp-Gly-Gln-Gly-  
 Thr-Leu-Val-Thr-Val-Ser-Ser.

25 10. A ligand or an antibody or fragment thereof according to  
 Claim 6 or 9 having a light chain variable domain which comprises  
 Asp-Phe-Met-Leu-Thr-Gln-Pro-His-Ser-Val-Ser-Glu-Ser-Pro-Gly-Lys-  
 Thr-Val-Ile-Ile-Ser-Cys-Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-  
 Tyr-Val-His-Trp-Tyr-Gln-Gln-Arg-Pro-Gly-Arg-Ala-Pro-Thr-Thr-Val-  
 30 Ile-Phe-Asp-Asp-Asp-Lys-Arg-Pro-Asp-Gly-Val-Pro-Asp-Arg-Phe-Ser-  
 Gly-Ser-Ile-Asp-Arg-Ser-Ser-Asn-Ser-Ala-Ser-Leu-Thr-Ile-Ser-Gly-  
 Leu-Gln-Thr-Glu-Asp-Glu-Ala-Asp-Tyr-Tyr-Cys-His-Ser-Tyr-Val-Ser-  
 Ser-Phe-Asn-Val-Phe-Gly-Gly-Gly-Thr-Lys-Leu-Thr-Val-Leu-Gly-Gln-  
 Pro-Lys-Ala-Ala-Pro-Ser-Val-Thr-Leu-Phe-Pro-Pro-Ser-Ser-Glu-Glu-  
 35 Leu-Gln.

- 32 -

11. A ligand or an antibody or fragment thereof according to any of the preceding claims, which has constant domains which are of or are derived from those of human origin.
- 05 12. An antibody or a fragment thereof according to any of Claims 3 to 11, in which only one of the arms thereof has an affinity for the CD3 antigen.
13. An antibody or a fragment thereof according to Claim 12 which is monovalent.
- 10 14. An antibody fragment according to Claim 13, in which one half of the antibody consists of a complete heavy chain and light chain and the other half consists of a similar but truncated heavy chain lacking the binding site for the light chain.
- 15 15. Recombinant DNA comprising a cloning vehicle or expression vector sequence and a nucleotide sequence which codes for at least one of amino acid sequences (a) to (e) as defined in Claim 1.
16. Recombinant DNA according to Claim 15, which comprises a cloning vehicle or expression vector sequence and at least one of the nucleotide sequences
- (a) AGCTTTCCAA TGGCC
- 20 (b) ACCATTAGTA CTAGTGGTGG TAGAACTTAC TATCGAGACT CCGTGAAGGG C
- (c) TTTCGGCAGT ACAGTGGTGG CTTTGATTAC
- (d) ACACTCAGCT CTGGTAACAT AGAAAACAAC TATGTGCAC
- (e) GATGATGATA AGAGACCGGA T
- (f) CATTCTTATG TTAGTAGTTT TAATGTT
- 25 17. Recombinant DNA according to Claim 15, which comprises a cloning vehicle or expression vector sequence and a nucleotide sequence which codes for one or both of the amino acid sequences as defined in Claims 9 and 10.

- 33 -

18. Recombinant DNA according to Claim 15, which comprises a cloning vehicle or expression vector sequence and one or both of the nucleotide sequences

- 05 (1) GAGGTCCAAC TGCTGGAGTC TGGGGGCGGT TTAGTGCAGC CTGGAGGGTC  
CCTGAGACTC TCCTGTGCAG CCTCAGGATT CACTTTCAGT AGCTTTCCAA  
TGGCCTGGGT CCGCCAGGCT CCAGGGAAGG GTCTGGAGTG GGTCTCAACC  
ATTAGTACTA GTGGTGGTAG AACTTACTAT CGAGACTCCG TGAAGGGCCG  
ATTCATATC TCCAGAGATA ATAGCAAAAA TACCCTATAC CTGCAATGA  
10 ATAGTCTGAG GGCTGAGGAC ACGGCCGTCT ATTACTGTGC AAAATTCGG  
CAGTACAGTG GTGGCTTTGA TTAGTGGGGC CAAGGGACCC TGGTCACCGT  
CTCCTCA
- (2) GACTTCATGC TGA CTAGCC CCACTCTGTG TCTGAGTCTC CCGGAAAGAC  
AGTCATTATT TCTTGACAC TCAGCTCTGG TAACATAGAA AACAACTATG  
TGCCTGGTA CCAGCAAAGG CCGGGAAGAG CTCCCACCAC TGTGATTTTC  
15 GATGATGATA AGAGACCGGA TGGTGTCCCT GACAGGTTCT CTGGCTCCAT  
TGACAGGTCT TCCAAC TCAG CCTCCCTGAC AATCAGTGGT CTGCAAACTG  
AAGATGAAGC TGA CTACTAC TGTCATTCTT ATGTTAGTAG TTTAATGTT  
TTCGGCGGTG GAACAAAGCT CACTGTCCTT

20 19. A process for the production of a ligand or an antibody or fragment thereof according to any of Claims 1 to 14 which comprises effecting expression of a ligand, antibody or fragment thereof by an expression system and, where appropriate, treating an antibody molecule to form a fragment thereof.

25 20. A process according to Claim 19, in which the expression system comprises recombinant DNA according to any of Claims 16 to 18.


21. Host cells comprising recombinant DNA according to any of Claims 15 to 18.

30 22. A ligand or an antibody or fragment thereof according to any of Claims 1 to 14 in the form of a pharmaceutical composition comprising a physiologically acceptable diluent or carrier.

23. A ligand or an antibody or fragment thereof according to any of Claims 1 to 14, for use in therapy.

- 34 -

24. The use of a ligand or an antibody or fragment thereof according to any of Claims 1 to 14 for the manufacture of a medicament for use in immunosuppression.
25. The use according to Claim 19, in which the medicament is for use in the treatment of recipients of a transplant.
- 05 26. A method of treating a patient having cancer or requiring immunosuppression which comprises administering to said patient a therapeutically effective amount of a ligand or an antibody or fragment thereof according to any of Claims 1 to 14.



Complementarity determining regions; CDR.

Position of oligonucleotide primer

Fig. 1




Fig.2

Fig.3a




Fig.3b







Fig.3c



6/11






Fig.4c



8/11




Fig.5




Fig.6




Fig.7a




Fig.7b

10/11




Fig.8




Fig.9




Fig.10

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 91/01726

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.C1.5	C 12 N 15/13	C 07 K 15/28 C 12 P 21/08
A 61 K 39/395		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.C1.5	A 61 K C 12 P	C 07 K C 12 N
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	European Journal of Immunology, volume 19, 1989, VCH Verlagsgesellschaft (Weinheim, DE) M. Clark et al.: "The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies", pages 381-388, see pages 383, 384, paragraph 1 (cited in the application)	1-12, 15 -25
Y	--- Clinical Chemistry, volume 35, no. 9, 1989, G.P. Moore: "Genetically engineered antibodies", pages 1849-1853, see the whole article, especially pages 1852, 1853	1-12, 15 -25
A	--- EP, A, 0336379 (ONCOGEN LTD) 11 October 1989, see the whole document	22-25
<p><sup>10</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
20-12-1991	31. VI. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	Miss J. MORTENSEN	



## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:  
 "Remark": although claim 26 is directed to a method of treatment of the human body the search has been carried out and based on the alleged effects of the composition".
2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only these claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort (justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## SA 51824

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

EP-A- 0336379	11-10-89	AU-A- 3242389	05-10-89
		CN-A- 1036988	08-11-89
		JP-A- 1304356	07-12-89